Cytomedix Inc. (CMXI) Announces Results Of RECOVER-Stroke Phase 2 Study; Provides Update On R&D Reorganization And Ongoing Launch Initiatives For Autologel™
5/6/2014 10:06:30 AM
GAITHERSBURG, Md., May 5, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, and its wholly owned subsidiary, Aldagen, Inc., announced today the preliminary efficacy and safety results at 90 days from the RECOVER-Stroke phase 2 study in patients with neurological damage arising from an ischemic stroke and treated with ALD-401. Observed improvements in the primary endpoint (mean modified Rankin Score or mRS) were not clinically or statistically significant. In light of this outcome, Cytomedix plans to discontinue further funding of the ALDH Bright Cell development program and close its R&D Facility in Durham, NC. The Company remains focused on its commercial launch initiative for AutoloGelTM with the goal of driving sales in the estimated $3.4 billion U.S. chronic wound market.
Help employers find you! Check out all the jobs and post your resume.
comments powered by